GenusLSE:GNS +1.22%75 FCF Margin % is 4.47% as of Dec. 2025, which is 41% above its 10-year median of 3.18. GuruFocus rates LSE:GNS with a GF Score™ of 75/100 and a GF Value™ of £20.62 (Fairly Valued). The stock has 5 warning signs investors should review. Among 958 Biotechnology companies, Genus ranks better than 79.96% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genus's Free Cash Flow for the
six
months ended in Dec. 2025 was £15.0 Mil. Genus's Revenue for the
six
months ended in Dec. 2025 was £335.6 Mil. Therefore, Genus's FCF Margin % for the quarter that ended in Dec. 2025 was 4.47%.
The historical rank and industry rank for Genus's FCF Margin % or its related term are showing as below:
LSE:GNS'
s FCF Margin % Range Over the Past 10 Years
Min: -5.24 Med: 3.18 Max: 7.22
Current: 6.82
During the past 13 years, the highest FCF Margin % of Genus was 7.22%. The lowest was -5.24%. And the median was 3.18%.
LSE:GNS's FCF Margin % is ranked better than 79.96% of 958
companies
in the Biotechnology industry
Industry Median: -85.21
vs LSE:GNS: 6.82
Genus FCF Margin % Related Terms
Genus FCF Margin % Historical Data
* Premium members only.
The historical data trend for Genus's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:GNS vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Genus's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Genus's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genus (LSE:GNS) has a FCF Margin % of 4.47% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genus and its competitors. This is 41% above median its historical median of 3.18. According to the industry distribution chart, Genus ranks #192 out of 958 companies in the Biotechnology industry, placing it in the top 20%.
Is Genus' FCF Margin % too high?
Genus' current FCF Margin % of 4.47% is 41% above median its 10-year median of 3.18. Based on the distribution chart, Genus ranks #192 out of 958 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genus has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genus' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #192 out of 958 companies for FCF Margin %. This places Genus in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genus and its competitors. Genus's current FCF Margin % is 4.47%, which is 41% above median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Based on GuruFocus' analysis, Genus (LSE:GNS) is currently considered Fairly Valued. The stock's GF Value™ is £20.62, compared to a current price of £21.58 — trading 4.7% above its estimated fair value. The current FCF Margin % is 4.47%, which is 41% above median its 10-year median of 3.18. Genus' overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genus (LSE:GNS), the current FCF Margin % is 4.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (LSE:GNS) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of £21.58 is trading 4.7% above its estimated GF Value™ of £20.62.
GuruFocus considers Genus to be Fairly Valued.
Key valuation signals for LSE:GNS:
FCF Margin %: 4.47% (41% above median its 10-year median of 3.18)
GF Value™: £20.62 vs. price of £21.58 (4.7% above fair value)
No single metric tells the full story. See the LSE:GNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
75GF Score
Get the complete analysis for LSE:GNS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:GNS has been successfully added to your 
